Outsmarting Nightmare: Drug Resistance in Acinetobacter baumannii.

Area of Science:

• Microbiology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Acinetobacter baumannii is a WHO-designated critical nosocomial pathogen.
• Carbapenem-resistant Acinetobacter baumannii (CRAB) causes urgent hospital-acquired infections, increasing mortality and healthcare costs.
• CRAB exhibits extensive drug resistance through mechanisms like efflux pumps, porins (OmpA), beta-lactamases, and mobile genetic elements.

Purpose of the Study:

• To provide a broad overview of CRAB resistance strategies and genetic determinants.
• To highlight emerging alternative therapies for CRAB infections.
• To identify research priorities for mitigating the global threat of CRAB.

Main Methods:

• Comprehensive literature review of CRAB resistance mechanisms.
• Analysis of genetic determinants including tet(A/B), cmlA, and mdfA.
• Evaluation of emerging interventions such as novel emergent phage therapy (NEPT) and ceramic nanoparticles (CNPs).

Main Results:

• CRAB employs diverse resistance mechanisms, leading to multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) strains.
• Conventional therapies are becoming increasingly ineffective against CRAB.
• Emerging therapies like NEPT and CNPs show promise in combating CRAB resistance.

Conclusions:

• A comprehensive understanding of CRAB resistance mechanisms is crucial.
• Novel therapeutic strategies are essential to overcome the limitations of current treatments.
• Further research into NEPT and CNPs is warranted to combat the growing threat of CRAB.